Cargando…

CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma

Natural Killer (NK) cells are known for their high intrinsic cytotoxic capacity, and the possibility to be applied as ‘off-the-shelf’ product makes them highly attractive for cell-based immunotherapies. In patients with multiple myeloma (MM), an elevated number of NK cells has been correlated with h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bexte, Tobias, Alzubi, Jamal, Reindl, Lisa Marie, Wendel, Philipp, Schubert, Ralf, Salzmann-Manrique, Emilia, von Metzler, Ivana, Cathomen, Toni, Ullrich, Evelyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176243/ https://www.ncbi.nlm.nih.gov/pubmed/35694192 http://dx.doi.org/10.1080/2162402X.2022.2081415

Ejemplares similares

P1354: CRISPR/CAS9 GENE EDITING OF IMMUNE CHECKPOINT RECEPTOR NKG2A IMPROVES THE ANTI-LEUKEMIC EFFICACY OF PRIMARY CD33-TARGETING CAR-NK CELLS.
por: Albinger, Nawid, et al.
Publicado: (2023)

Immunotherapy with NK cells: recent developments in gene modification open up new avenues
por: Reindl, Lisa Marie, et al.
Publicado: (2020)

Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy
por: Wendel, Philipp, et al.
Publicado: (2021)

Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy
por: Ullrich, Evelyn, et al.
Publicado: (2022)

The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells
por: Kaulfuss, Meike, et al.
Publicado: (2023)

Targeted genome editing restores T cell differentiation in a humanized X-SCID pluripotent stem cell disease model
por: Alzubi, Jamal, et al.
Publicado: (2017)

NKG2A is a NK cell exhaustion checkpoint for HCV persistence
por: Zhang, Chao, et al.
Publicado: (2019)

TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity
por: Mussolino, Claudio, et al.
Publicado: (2014)

New prospects on the NKG2D/NKG2DL system for oncology
por: Ullrich, Evelyn, et al.
Publicado: (2013)

Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation
por: Ullrich, Evelyn, et al.
Publicado: (2016)

S256: HLA-E/NKG2A CHECKPOINT DRIVES MULTIPLE MYELOMA RESISTANCE TO CAR-NK THERAPY
por: Encinas, Jessica, et al.
Publicado: (2023)

TALE-PvuII Fusion Proteins – Novel Tools for Gene Targeting
por: Yanik, Mert, et al.
Publicado: (2013)

Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer
por: Fisher, Jack G., et al.
Publicado: (2022)

NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme
por: Murad, Shafiq, et al.
Publicado: (2022)

CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
por: Elmas, Ezgi, et al.
Publicado: (2022)

Unleashing the power of NK cells in anticancer immunotherapy
por: Vogler, Meike, et al.
Publicado: (2021)

Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells
por: Mosti, Laura, et al.
Publicado: (2021)

Potential of the NKG2D/NKG2DL Axis in NK Cell-Mediated Clearance of the HIV-1 Reservoir
por: Desimio, Maria G., et al.
Publicado: (2019)

Automated generation of gene-edited CAR T cells at clinical scale
por: Alzubi, Jamal, et al.
Publicado: (2020)

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
por: André, Pascale, et al.
Publicado: (2018)

Non-integrating gamma-retroviral vectors as a versatile tool for transient zinc-finger nuclease delivery
por: Bobis-Wozowicz, Sylwia, et al.
Publicado: (2014)

Genome Editing With TALEN, CRISPR-Cas9 and CRISPR-Cas12a in Combination With AAV6 Homology Donor Restores T Cell Function for XLP
por: Houghton, Benjamin C., et al.
Publicado: (2022)

Inhibitory NKG2A(+) and absent activating NKG2C(+) NK cell responses are associated with the development of EBV(+) lymphomas
por: Vietzen, Hannes, et al.
Publicado: (2023)

Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma
por: Tognarelli, Sara, et al.
Publicado: (2018)

Clinical genome editing to treat sickle cell disease—A brief update
por: Zarghamian, Parinaz, et al.
Publicado: (2023)

Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors
por: Koch, Christine, et al.
Publicado: (2017)

Increased serum NKG2D-ligands and downregulation of NKG2D in peripheral blood NK cells of patients with major burns
por: Haik, Josef, et al.
Publicado: (2015)

Rescue of DNA-PK Signaling and T-Cell Differentiation by Targeted Genome Editing in a prkdc Deficient iPSC Disease Model
por: Rahman, Shamim H., et al.
Publicado: (2015)

Monalizumab: inhibiting the novel immune checkpoint NKG2A
por: van Hall, Thorbald, et al.
Publicado: (2019)

Polyclonal Expansion of NKG2C(+) NK Cells in TAP-Deficient Patients
por: Béziat, Vivien, et al.
Publicado: (2015)

High Metabolic Function and Resilience of NKG2A-Educated NK Cells
por: Highton, Andrew J., et al.
Publicado: (2020)

Responsiveness to Influenza Vaccination Correlates with NKG2C-Expression on NK Cells
por: Riese, Peggy, et al.
Publicado: (2020)

Dissection of the NKG2C NK cell response against Puumala Orthohantavirus
por: Vietzen, Hannes, et al.
Publicado: (2021)

CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells
por: Mohammadian Gol, Tahereh, et al.
Publicado: (2023)

Cell-Based Models of ‘Cytokine Release Syndrome’ Endorse CD40L and Granulocyte–Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy
por: Dibas, Ala, et al.
Publicado: (2023)

A Role for NKG2D in NK Cell–Mediated Resistance to Poxvirus Disease
por: Fang, Min, et al.
Publicado: (2008)

Activating KIRs and NKG2C in Viral Infections: Toward NK Cell Memory?
por: Della Chiesa, Mariella, et al.
Publicado: (2015)

NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML
por: Schlegel, Patrick, et al.
Publicado: (2015)

Endothelial cells express NKG2D ligands and desensitize antitumor NK responses
por: Thompson, Thornton W, et al.
Publicado: (2017)

Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies
por: Melero, Ignacio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lkck7lks616bggn9ac1i4qsqnj